Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 04 04:00PM ET
3.52
Dollar change
+0.08
Percentage change
2.32
%
Index- P/E- EPS (ttm)-1.08 Insider Own27.73% Shs Outstand8.90M Perf Week7.97%
Market Cap31.41M Forward P/E- EPS next Y-2.19 Insider Trans0.00% Shs Float6.45M Perf Month-0.00%
Income-9.63M PEG- EPS next Q-0.28 Inst Own10.76% Short Float0.88% Perf Quarter12.46%
Sales5.40M P/S5.82 EPS this Y-11.70% Inst Trans0.38% Short Ratio1.58 Perf Half Y-3.56%
Book/sh0.84 P/B4.21 EPS next Y-108.57% ROA-63.39% Short Interest0.06M Perf Year25.49%
Cash/sh1.01 P/C3.49 EPS next 5Y- ROE-79.76% 52W Range2.44 - 6.16 Perf YTD-36.00%
Dividend Est.- P/FCF- EPS past 5Y52.24% ROI-129.32% 52W High-42.83% Beta1.47
Dividend TTM- Quick Ratio3.15 Sales past 5Y93.13% Gross Margin- 52W Low44.39% ATR (14)0.38
Dividend Ex-Date- Current Ratio3.15 EPS Y/Y TTM48.02% Oper. Margin-188.94% RSI (14)51.55 Volatility9.43% 11.51%
Employees8 Debt/Eq0.00 Sales Y/Y TTM-40.47% Profit Margin-178.54% Recom1.00 Target Price19.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q23.44% Payout- Rel Volume0.30 Prev Close3.44
Sales Surprise92.60% EPS Surprise33.33% Sales Q/Q647.66% EarningsNov 14 AMC Avg Volume36.10K Price3.52
SMA201.82% SMA503.76% SMA200-11.06% Trades Volume10,886 Change2.32%
Date Action Analyst Rating Change Price Target Change
Mar-25-21Initiated Piper Sandler Overweight $6
Mar-19-21Initiated Cantor Fitzgerald Overweight $6
May-12-20Downgrade Piper Sandler Overweight → Neutral $5 → $2.50
May-30-19Initiated ROTH Capital Buy
Mar-01-19Initiated Janney Buy
Dec-03-18Upgrade Piper Jaffray Neutral → Overweight
Nov-26-24 11:00AM
Nov-14-24 04:30PM
Oct-22-24 08:20AM
Sep-26-24 02:33PM
Aug-28-24 08:00AM
04:30PM Loading…
Aug-14-24 04:30PM
Aug-12-24 07:00AM
Jun-28-24 11:52AM
May-15-24 11:53PM
04:15PM
Apr-08-24 07:00AM
Mar-25-24 05:45PM
Mar-22-24 12:30PM
Jan-22-24 07:30AM
Jan-08-24 09:31AM
08:24AM Loading…
08:24AM
Dec-21-23 11:00AM
Dec-11-23 07:00AM
Nov-09-23 05:00PM
Sep-11-23 07:00AM
Aug-30-23 08:00AM
Aug-25-23 12:07PM
Aug-17-23 09:03AM
Aug-14-23 04:30PM
Aug-07-23 07:00AM
Jul-26-23 07:00AM
Jul-22-23 08:12AM
Jul-10-23 07:00AM
Jun-26-23 07:00AM
Jun-12-23 07:00AM
06:30AM Loading…
May-31-23 06:30AM
May-17-23 06:11AM
May-08-23 07:30AM
May-01-23 07:30AM
Mar-22-23 08:10AM
Dec-13-22 07:23PM
07:00AM
Nov-22-22 07:28AM
07:00AM
Nov-10-22 05:35PM
04:05PM
Sep-13-22 07:00AM
Sep-08-22 07:00AM
Aug-11-22 04:22PM
Aug-04-22 04:37PM
Jun-15-22 07:06AM
May-13-22 07:00AM
May-04-22 10:30AM
Apr-26-22 07:00AM
Mar-17-22 05:45PM
Mar-07-22 04:05PM
Feb-17-22 01:08PM
Feb-16-22 04:30PM
Feb-08-22 04:05PM
Jan-20-22 06:38AM
Jan-19-22 04:49PM
Jan-06-22 08:53AM
Dec-31-21 09:40AM
Dec-09-21 07:00AM
Nov-18-21 04:05PM
Nov-10-21 04:05PM
Oct-08-21 09:24AM
Sep-07-21 04:05PM
Aug-20-21 12:00PM
Aug-19-21 04:05PM
Aug-10-21 04:01PM
Aug-09-21 06:57AM
Jul-28-21 04:05PM
Jul-06-21 07:00AM
Jun-29-21 09:01AM
Jun-16-21 04:05PM
May-20-21 04:06AM
May-12-21 04:05PM
02:45PM
Apr-29-21 04:05PM
Apr-27-21 07:41PM
Apr-08-21 03:23PM
Apr-07-21 08:32AM
Mar-16-21 04:57PM
Mar-15-21 07:00AM
Mar-12-21 08:00AM
Mar-11-21 04:10PM
Mar-09-21 04:12PM
Mar-03-21 07:00AM
Mar-01-21 05:03AM
Jan-13-21 07:00AM
Jan-05-21 07:00AM
Nov-30-20 02:30AM
Nov-09-20 04:01PM
03:15PM
Nov-02-20 07:00AM
Sep-17-20 07:00AM
Aug-10-20 04:00PM
Jun-30-20 07:00AM
Jun-23-20 07:00AM
Jun-10-20 02:14PM
Jun-02-20 06:34AM
May-29-20 08:00AM
May-13-20 05:01PM
May-11-20 04:05PM
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.